Orchid Chemicals gets USFDA nod for anti-depression capsule

Drug firm Orchid Chemicals & Pharmaceuticals today said it has received final approval from the US health regulator for its generic Venlafaxine capsules, used in the treatment of depression.

The final approval from the United States Food and Drug Administration (USFDA) is for its abbreviated new drug application (ANDA) for Venlafaxine extended release capsules in strengths of 37.5 mg, 75 mg and 150 mg, Orchid Chemicals & Pharmaceuticals said in a filing to the Bombay Stock Exchange (BSE).

Also read: Dr Reddy's gets USFDA ok for deep vein thrombosis injection

Venlafaxine extended release capsules are used for treating major depressive disorders (MDD) and falls under the central nervous system (CNS) category.

Venlafaxine was introduced by drug-maker Wyeth in 1993 under the brand name Effexor.

Shares of Orchid Chemicals & Pharmaceuticals were being quoted at Rs 254 apiece in afternoon trade on the BSE today, up 0.89% from their previous close.